Literature DB >> 25966421

Head and neck second primary cancer rates in the human papillomavirus era: A population-based analysis.

Dayssy Alexandra Diaz1, Isildinha M Reis2, Donald T Weed3, Nagy Elsayyad1, Michael Samuels1, Matthew C Abramowitz1.   

Abstract

BACKGROUND: Patients with head and neck cancer are at high risk for second primary malignancies. Human papillomavirus (HPV)-driven tumors are generally high-grade oropharyngeal cancers. We analyzed the incidence of second primary malignancy of the head and neck in patients with primary squamous cell carcinoma (SCC) of the head and neck and temporal trends in the HPV era.
METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was queried for patients with SCC of the head and neck (range, 1973-2008). Cumulative incidence rates of second primary malignancy of the head and neck were compared based on competing risk analysis.
RESULTS: A total of 104,639 cases were included in this study, of which 4616 patients had second primary malignancy of the head and neck. Oropharyngeal cancer incidence increased over time. Estimated incidence rate/10,000 person-years (105.5, 80.6, and 50.2 for 1973-1989, 1990-1999, and 2000-2008, respectively) and cumulative incidence rates (10-year rates of 6.68%, 5.72%, and 4.59% for 1973-1989, 1990-1999, and 2000-2008, respectively) of second primary malignancies of the head and neck for patients with oropharyngeal cancer decreased over time (p < .001). The second primary malignancy of the head and neck incidence rate was significantly lower in patients with high-grade oropharyngeal cancer from 2000 to 2008 (30.3 vs 65.5 and 54.6 from 1973-1989 and 1990-1999, respectively; p < .001).
CONCLUSION: The incidence of second primary malignancy of the head and neck in patients with head and neck cancer has decreased over time. This is driven by lower rates in patients with high-grade oropharyngeal cancer, is temporally related with increases in HPV-associated oropharyngeal cancer, and suggests that incidence rates of second primary malignancy of the head and neck may be lower for HPV-associated cancer.
© 2015 Wiley Periodicals, Inc. Head Neck 38: E873-E883, 2016. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  Epidemiology; Surveillance; and End Results (SEER); head and neck cancer; human papillomavirus (HPV); oropharyngeal cancer; second cancers

Mesh:

Year:  2015        PMID: 25966421     DOI: 10.1002/hed.24119

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  4 in total

1.  Two for the price of one: Prevalence, demographics and treatment implications of multiple HPV mediated Head and Neck Cancers.

Authors:  William Strober; Sachie Shishido; Burton Wood; James S Lewis; Krystle Kuhs; Robert L Ferris; Daniel L Faden
Journal:  Oral Oncol       Date:  2019-11-22       Impact factor: 5.337

2.  Development of second primary malignancies after transoral surgery in human papilloma virus-positive oropharyngeal squamous cell carcinoma.

Authors:  Katelyn Stepan; Ethan Craig; Scott Andrew Skillington; Brian C Deutsch; Stephanie Chen; Nneoma S Wamkpah; Craig A Bollig; Dorina Kallogjeri; Wade L Thorstad; Sidharth V Puram; Patrik Pipkorn; Ryan S Jackson
Journal:  Head Neck       Date:  2022-02-17       Impact factor: 3.821

Review 3.  Human papillomavirus and head and neck carcinomas: focus on evidence in the babel of published data.

Authors:  P Morbini; M Benazzo
Journal:  Acta Otorhinolaryngol Ital       Date:  2016-08       Impact factor: 2.124

4.  A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 1 (Head and Neck Surgery).

Authors:  Pavel Dulguerov; Martina A Broglie; Guido Henke; Marco Siano; Paul Martin Putora; Christian Simon; Daniel Zwahlen; Gerhard F Huber; Giorgio Ballerini; Lorenza Beffa; Roland Giger; Sacha Rothschild; Sandro V Negri; Olgun Elicin
Journal:  Front Oncol       Date:  2019-10-24       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.